260 related articles for article (PubMed ID: 34444777)
1. Omega-3 Polyunsaturated Fatty Acid: A Pharmaco-Nutraceutical Approach to Improve the Responsiveness to Ursodeoxycholic Acid.
Thérien A; Cieślak A; Verreault M; Perreault M; Trottier J; Gobeil S; Vohl MC; Barbier O
Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444777
[TBL] [Abstract][Full Text] [Related]
2. The effect of ursodeoxycholic acid on the relative expression of the lipid metabolism genes in mouse cholesterol gallstone models.
Fan N; Meng K; Zhang Y; Hu Y; Li D; Gao Q; Wang J; Li Y; Wu S; Cui Y
Lipids Health Dis; 2020 Jul; 19(1):158. PubMed ID: 32615989
[TBL] [Abstract][Full Text] [Related]
3. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.
He H; Mennone A; Boyer JL; Cai SY
Hepatology; 2011 Feb; 53(2):548-57. PubMed ID: 21274875
[TBL] [Abstract][Full Text] [Related]
4. N-3 Polyunsaturated Fatty Acids Stimulate Bile Acid Detoxification in Human Cell Models.
Cieślak A; Trottier J; Verreault M; Milkiewicz P; Vohl MC; Barbier O
Can J Gastroenterol Hepatol; 2018; 2018():6031074. PubMed ID: 29850457
[TBL] [Abstract][Full Text] [Related]
5. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
6. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting Endoplasmic Reticulum (ER) Stress Induced by Disturbed Flow.
Chung J; Kim KH; Lee SC; An SH; Kwon K
Mol Cells; 2015 Oct; 38(10):851-8. PubMed ID: 26442866
[TBL] [Abstract][Full Text] [Related]
9. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
[TBL] [Abstract][Full Text] [Related]
10. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
[TBL] [Abstract][Full Text] [Related]
11. Use of ursodeoxycholic acid in patients with liver disease.
Angulo P
Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
[TBL] [Abstract][Full Text] [Related]
12. Bile Acids as Signaling Molecules: Role of Ursodeoxycholic Acid in Cholestatic Liver Disease.
Cifuentes-Silva E; Cabello-Verrugio C
Curr Protein Pept Sci; 2024; 25(3):206-214. PubMed ID: 37594109
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of cholestatic liver diseases].
Gatzen M; Pausch J
Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
[TBL] [Abstract][Full Text] [Related]
14. All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.
Cai SY; Mennone A; Soroka CJ; Boyer JL
J Pharmacol Exp Ther; 2014 Apr; 349(1):94-8. PubMed ID: 24492652
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.
Jazrawi RP; de Caestecker JS; Goggin PM; Britten AJ; Joseph AE; Maxwell JD; Northfield TC
Gastroenterology; 1994 Jan; 106(1):134-42. PubMed ID: 8276175
[TBL] [Abstract][Full Text] [Related]
16. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
17. [Bile acids in liver diseases--current indications].
Stiehl A
Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
[TBL] [Abstract][Full Text] [Related]
18. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
19. New therapeutical indications of ursodeoxycholic acid.
Copaci I; Micu L; Iliescu L; Voiculescu M
Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
[TBL] [Abstract][Full Text] [Related]
20. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Pojer C; Zenz R; Lammert F; Stieger B; Meier PJ; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2001 Jul; 121(1):170-83. PubMed ID: 11438506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]